Featured Research

from universities, journals, and other organizations

Regular Salmeterol For Asthma: More Evidence Of Long-term Problems

Date:
July 15, 2008
Source:
Wiley-Blackwell
Summary:
People with asthma who regularly use salmeterol are at a greater risk of non-fatal serious adverse events than those using placebos. This conclusion was arrived at by a team of Cochrane researchers who drew together data from 26 trials involving 62,630 patients.

People with asthma who regularly use salmeterol are at a greater risk of non-fatal serious adverse events than those using placebos. This conclusion was arrived at by a team of Cochrane Researchers who drew together data from 26 trials involving 62,630 patients.

The researchers found that over a four to six month period, for every thousand people treated for asthma there were 45 who suffered a serious adverse event on regular salmeterol, compared to only 40 if a placebo inhaler was given.

Salmeterol is a long-acting beta2-agonist. It is inhaled by people with asthma twice daily, and relieves symptoms for up to 12 hours. It is generally recommended for use along with corticosteroid inhalers (also known as preventer inhalers).

Over the last decade some researchers and practitioners have expressed anxieties that although salmeterol can relieve asthma symptoms, it could cause long-term problems.

"We found that the biggest increase in risk was seen in people with asthma who were not taking inhaled corticosteroids; however, there is no guarantee that inhaled corticosteroids abolish the risk all together," says lead researcher Christopher Cates who works in Community Health Sciences at St George's, London, UK.

The authors recommend that people should follow the manufacturer's advice not to increase the dose of salmeterol during an exacerbation. Furthermore regular salmeterol should not be used as an alternative to inhaled corticosteroids. Benefits and risks both need to be considered before embarking on long term treatment with regular salmeterol.

Work is currently in progress on a similar assessment of formoterol (another long-acting beta2-agonist).


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Regular Salmeterol For Asthma: More Evidence Of Long-term Problems." ScienceDaily. ScienceDaily, 15 July 2008. <www.sciencedaily.com/releases/2008/07/080715204837.htm>.
Wiley-Blackwell. (2008, July 15). Regular Salmeterol For Asthma: More Evidence Of Long-term Problems. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2008/07/080715204837.htm
Wiley-Blackwell. "Regular Salmeterol For Asthma: More Evidence Of Long-term Problems." ScienceDaily. www.sciencedaily.com/releases/2008/07/080715204837.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins